Enable job alerts via email!
Boost your interview chances
Create a job specific, tailored resume for higher success rate.
A leading pharmaceutical company seeks an experienced Quality Assurance Manager for its Framingham location. The role entails overseeing validation activities, ensuring compliance with regulations, and fostering strategic partnerships across teams to uphold data integrity and quality standards.
Replimune’s mission is to revolutionize cancer treatment with therapies designed to activate a powerful and durable full-body anti-tumor response, boldly transforming cancer care because patient’s lives depend on it. We imagine a world where cancer is a curable disease.
People are at the center of everything we do, and when it comes to our employees, we make it personal. With a deep sense of purpose, an innovative and collaborative culture, a competitive and forward-looking total rewards program, everyone at Replimune has a unique opportunity to contribute to the meaningful work we do which could impact the lives of patients.
Join us, as we reshape the future.
This role provides cross-functional support for GxP activities as they relate to validation activities throughout the GxP organization. This position will provide comprehensive mentoring, oversight and monitoring of compliance for all applicable regulations spanning operations and IT relating to achieving and maintaining the validated state of facilities, utilities and equipment.
This position is based in our Framingham location and typically has a 5-day on-site expectation.
Bachelor's degree required in the life sciences.
Replimune Group, Inc., headquartered in Woburn, MA, was founded in 2015 with the mission to transform cancer treatment by pioneering the development of a novel portfolio of oncolytic immunotherapies. Replimune’s proprietary RPx platform is based on a potent HSV-1 backbone intended to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The RPx platform is designed to have a unique dual local and systemic activity consisting of direct selective virus-mediated killing of the tumor resulting in the release of tumor derived antigens and altering of the tumor microenvironment to ignite a strong and durable systemic response. The RPx product candidates are expected to be synergistic with most established and experimental cancer treatment modalities, leading to the versatility to be developed alone or combined with a variety of other treatment options. For more information, please visit www.replimune.com.
We are an Equal Opportunity Employer.